At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
Tissue Repair Cells (TRC) +1 morebiological
Likely dose
Tissue Repair Cells (TRC) 50 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy
In Brief
A Phase 2 clinical trial evaluating Tissue Repair Cells (TRC) and Control for Alveolar Bone Loss. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The purpose of this research is to determine if a subject's own bone marrow tissue can help regenerate bone in the area of his/her jaw where a tooth has been removed using Tissue Repair Cell (TRC) Therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlveolar Bone Loss
CountriesUnited States
CollaboratorsVericel Corporation
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
First PostedSep 2008
Primary CompletionDec 2011
Study CompletionMay 2012
TodayJul 2026
First PostedSep 19, 2008
Enrollment StartJun 1, 2008
Primary CompletionDec 1, 2011
Study CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 17.8 years ago
Interventions
Tissue Repair Cells (TRC)biological
30-50 ml of bone marrow is aspirated from subject and processed into TRC autologous bone marrow tissue graft. 10ml of TRC will be absorbed onto gelfoam carrier and placed in extraction socket.
Controldevice
Control subjects only receive standard gelfoam carrier. It promotes healing after tooth extraction